DPY19L3 (M-17): sc-241393



The Power to Question

BACKGROUND

Consisting of around 63 million bases with over 1,400 genes, chromosome 19 makes up over 2% of human genomic DNA. Chromosome 19 includes a diversity of interesting genes and is recognized for having the greatest gene density of the human chromosomes. It is the genetic home for a number of immunoglobulin superfamily members including the killer cell and leukocyte lg-like receptors, a number of ICAMs, the CEACAM and PSG family, and Fc α receptors. Key genes for eye color and hair color also map to chromosome 19. Peutz-Jeghers syndrome, spinocerebellar ataxia type 6, the stroke disorder CADASIL, hypercholesterolemia and Insulin-dependent diabetes have been linked to chromosome 19. Translocations with chromosome 19 and chromosome 14 can be seen in some lymphoproliferative disorders and typically involve the proto-oncogene BCL3.

REFERENCES

- Zimmermann, W., et al. 1988. Chromosomal localization of the carcinoembryonic antigen gene family and differential expression in various tumors. Cancer Res. 48: 2550-2554.
- LaPoint, S.F., et al. 2000. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). Adv. Anat. Pathol. 7: 307-321.
- 3. Trettel, F., et al. 2000. A fine physical map of the CACNA1A gene region on 19p13.1-p13.2 chromosome. Gene 241: 45-50.
- 4. Buchet-Poyau, K., et al. 2002. Search for the second Peutz-Jeghers syndrome locus: exclusion of the STK13, PRKCG, KLK10, and PSCD2 genes on chromosome 19 and the STK11IP gene on chromosome 2. Cytogenet. Genome Res. 97: 171-178.
- Moodie, S.J., et al. 2002. Analysis of candidate genes on chromosome 19 in coeliac disease: an association study of the KIR and LILR gene clusters. Eur. J. Immunogenet. 29: 287-291.
- Grimwood, J., et al. 2004. The DNA sequence and biology of human chromosome 19. Nature 428: 529-535.
- Parham, P. 2005. Immunogenetics of killer cell immunoglobulin-like receptors. Mol. Immunol. 42: 459-462.
- Brocke-Heidrich, K., et al. 2006. BCL3 is induced by IL-6 via Stat3 binding to intronic enhancer HS4 and represses its own transcription. Oncogene 25: 7297-7304.
- 9. Vikelis, M., et al. 2007. A novel CADASIL-causing mutation in a stroke patient. Swiss Med. Wkly. 137: 323-325.

CHROMOSOMAL LOCATION

Genetic locus: DPY19L3 (human) mapping to 19q13.11; Dpy19l3 (mouse) mapping to 7 B2.

SOURCE

DPY19L3 (M-17) is an affinity purified goat polyclonal antibody raised against a peptide mapping near the C-terminus of DPY19L3 of mouse origin.

PRODUCT

Each vial contains 200 μg IgG in 1.0 ml of PBS with <0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-241393 P, ($100 \mu g$ peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

DPY19L3 (M-17) is recommended for detection of DPY19L3 of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000); non cross-reactive with DPY19L1, DPY19L2 or DPY19L4.

Suitable for use as control antibody for DPY19L3 siRNA (h): sc-97857, DPY19L3 siRNA (m): sc-143164, DPY19L3 shRNA Plasmid (h): sc-97857-SH, DPY19L3 shRNA Plasmid (m): sc-143164-SH, DPY19L3 shRNA (h) Lentiviral Particles: sc-97857-V and DPY19L3 shRNA (m) Lentiviral Particles: sc-143164-V.

Molecular Weight of DPY19L3: 83 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3801 fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scht.com